(Q42644977)

4 November 2017

Reduced intravenous glutathione in the treatment of early Parkinson's disease (English)

1 reference

4 November 2017

1 reference

1 reference

6

1 reference

4 November 2017

Sechi G

1

1 reference

4 November 2017

Deledda MG

2

1 reference

4 November 2017

Bua G

3

1 reference

4 November 2017

Satta WM

4

1 reference

4 November 2017

Deiana GA

5

1 reference

4 November 2017

Rosati G

7

1 reference

4 November 2017

1 October 1996

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

4 November 2017

1 reference

4 November 2017

20

1 reference

4 November 2017

1159-1170

1 reference

4 November 2017

7

1 reference

Blood-brain barrier restriction of peptides and the low uptake of enkephalins

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

The protective influence of the locus ceruleus on the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

New insights into the cause of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Glutathione and Related γ-Glutamyl Compounds: Biosynthesis and Utilization

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Selegiline as initial treatment in de novo parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Blood-brain barrier: interface between internal medicine and the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Parkinson's disease: a disorder due to nigral glutathione deficiency?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Bromocriptine: low-dose therapy in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Neuropathology of the locus ceruleus: a semi-quantitative study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Treatment of Parkinsonism With Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2896%2900103-0

7 January 2021

10.1016/S0278-5846(96)00103-0

Identifiers

DOI

1 reference

4 November 2017

1 reference